Comparison 1. Dexrazoxane versus no dexrazoxane or placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical heart failure	8	1561	Risk Ratio (M‐H, Fixed, 95% CI)	0.18 [0.10, 0.32]
2 Heart failure (i.e. clinical and subclinical heart failure combined)	5	643	Risk Ratio (M‐H, Fixed, 95% CI)	0.29 [0.20, 0.41]
3 Response rate	6	1021	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.78, 1.02]
4 Progression‐free survival	4		Hazard ratio (Fixed, 95% CI)	1.01 [0.86, 1.18]
5 Overall survival	4		Hazard ratio (Fixed, 95% CI)	1.04 [0.88, 1.23]
6 Adverse effects: thrombocytopenia grade 3 or 4	2	293	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.49, 2.21]
7 Adverse effects: abnormal platelet count at nadir grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.53, 1.59]
8 Adverse effects: abnormal platelet count at recovery grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.16, 4.15]
9 Adverse effects: neutropenia grade 3 or 4	2	293	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.90, 1.21]
10 Adverse effects: abnormal granulocyte count at nadir grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.97, 1.11]
11 Adverse effects: abnormal granulocyte count at recovery grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.59, 1.21]
12 Adverse effects: abnormal white blood cell count at nadir grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [1.05, 1.29]
13 Adverse effects: abnormal white blood cell count at recovery grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.36, 1.31]
14 Adverse effects: anaemia grade 3 or 4	3	509	Risk Ratio (M‐H, Fixed, 95% CI)	1.40 [1.08, 1.81]
15 Adverse effects: stomatitis grade 3 or 4	4	914	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.60, 1.21]
16 Adverse effects: nausea grade 3 or 4	3	698	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.49, 0.94]
17 Adverse effects: vomiting grade 3 or 4	3	698	Risk Ratio (M‐H, Fixed, 95% CI)	0.79 [0.55, 1.14]
18 Adverse effects: neurotoxicity grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.12, 2.26]
19 Adverse effects: pain on injection grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.51 [0.34, 6.72]
20 Adverse effects: anorexia grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.57, 1.64]
21 Adverse effects: alopecia grade 3 or 4	3	698	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.94, 1.11]
22 Adverse effects: phlebitis grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.54 [0.35, 6.75]
23 Adverse effects: diarrhoea grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.17 [0.49, 2.79]
24 Adverse effects: fever grade 3 or 4	2	534	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [0.81, 2.53]
25 Adverse effects: secondary malignant disease	2	421	Risk Ratio (M‐H, Fixed, 95% CI)	1.39 [0.28, 6.90]